Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...
Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
In this video, Xiuning Le, MD, PhD, discusses the state of the pipeline for developing EGFR-mutated lung cancer treatments.
The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...
DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...
Systemic Bio™, a 3D Systems company (NYSE: DDD), has been named the winner of the prestigious SLAS 2025 Innovation Award. This award recognizes groundbreaking technological advancements poised to ...
Celltrion launches ADC cancer drug trials in U.S. while planning additional INDs Celltrion accelerates its global drug ...
Comparative outcomes of neuroendocrine tumors in the historically underserved population of Bronx, NY: Montefiore Einstein Comprehensive Cancer Center. Pamrevlumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback